The U.S. Food and Drug Administration approved somapacitan-beco (Sogroya, Novo Nordisk) on Thursday as the first once-weekly growth hormone for children with Turner syndrome, expanding a treatment option that cuts annual injections from 365 to 52.
The agency cleared the long-acting analog for patients aged 2.5 years and older who have growth failure associated with the chromosomal condition, which affects roughly one in 2,000 female newborns, Medscape reported. The drug is already indicated for growth hormone deficiency in adults and children, as well as for idiopathic short stature, Noonan syndrome, and short stature in children born small for gestational age.
REAL8 Trial Shows Comparable Growth Velocity
The approval rests on the phase 3 REAL8 study (NCT05330325), a multicenter, randomized, open-label, active-comparator trial that enrolled 105 girls aged 2.5 to 10 years, all of whom were born small for gestational age with no catch-up growth by age two.
Participants were assigned in a 2:1 ratio to once-weekly somapacitan-beco 0.24 mg/kg/week (n=68) or once-daily somatropin 0.05 mg/kg/day (n=37), a dose below the U.S. maximum of 0.067 mg/kg/day for Turner syndrome, according to the company’s announcement on PRNewswire.

At week 52, mean annualized height velocity — the primary endpoint — reached 8.9 cm/year with somapacitan-beco versus 9.7 cm/year with daily somatropin, an estimated treatment difference of -0.8 cm/year (95% CI -1.58 to 0.07). The change in height standard deviation score from baseline was 0.77 and 0.86, respectively, EMPR reported.
“Daily growth hormone therapy works well, but staying consistent with treatment over time can be difficult — especially in conditions like Turner Syndrome, where families may struggle with managing multiple comorbidities and medications.”
said Dr. Aristides Maniatis, founder of Rocky Mountain Pediatric Endocrinology and a REAL8 investigator, in comments to the company. “By offering a once-weekly treatment option, Sogroya provides 313 injection-free days each year.”
Weekly Growth Hormone Cuts 313 Needle Sticks Yearly
- Girls with Turner syndrome can now receive growth hormone once a week instead of every day, reducing the burden of 313 fewer needle sticks per year.
- In the key trial, weekly dosing produced height gains statistically similar to daily injections over one year.
- The drug is delivered via a prefilled pen in three strengths (5 mg, 10 mg, 15 mg), simplifying dose preparation for caregivers.
Safety Profile Consistent With Growth Hormone Class
Adverse reactions occurring in 10% or more of pediatric participants receiving somapacitan-beco included respiratory tract infection, nasopharyngitis, ear infection, pyrexia, diarrhea, vomiting, and injection-site reactions, Contemporary Pediatrics noted. The most common side effects across pediatric indications also include cough, headache, and pain in extremity. In adults, the profile shifts toward back pain, arthralgia, peripheral edema, and adrenal insufficiency. Trial participants are continuing in a two-year safety extension phase.
| Metric | Somapacitan-beco (Weekly) | Somatropin (Daily) |
|---|---|---|
| Patients (n) | 68 | 37 |
| Annualized Height Velocity (cm/yr) | 8.9 | 9.7 |
| Height SDS Change | 0.77 | 0.86 |
| Dose | 0.24 mg/kg/week | 0.05 mg/kg/day |
Fatty Acid Modification Enables Weekly Dosing
Somapacitan-beco is a recombinant human growth hormone analog modified with a fatty acid side chain that enables reversible albumin binding, extending half-life to allow weekly dosing. The approval marks the fifth pediatric growth indication for the product since its initial U.S. clearance for adult growth hormone deficiency in 2020. Novo Nordisk funded the REAL8 trial and holds the marketing authorization.

Turner syndrome results from complete or partial monosomy of the X chromosome. Beyond short stature, patients frequently require multidisciplinary care for congenital heart defects, renal anomalies, and ovarian insufficiency. Reducing injection frequency may improve adherence during the prolonged treatment window that often spans childhood into adolescence.
Novo Nordisk traces its origins to the 1920s with the founding of Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium, which merged in 1989 to form the current company. Headquartered in Denmark, it employs approximately 69,500 people across 80 countries and markets its products in roughly 170 nations.
In 1985, the company introduced the first insulin pen device, Novopen, a milestone in delivery technology that foreshadowed the prefilled pen used for somapacitan-beco today. In 2023, its market capitalization exceeded the GDP of Denmark, making it the highest-valued company in Europe.
Contraindications & When to Consult a Doctor
- Somapacitan-beco is contraindicated in patients with acute critical illness, active malignancy, or known hypersensitivity to somapacitan or any excipient.
- Monitor for signs of increased intracranial pressure (headache, vomiting, visual changes), glucose intolerance, thyroid dysfunction, and slipped capital femoral epiphysis during treatment.
- Families should contact their endocrinologist if injection-site reactions persist, if the child develops severe abdominal pain, or if growth velocity decelerates unexpectedly.
Participants remain enrolled in the two-year extension of REAL8 to assess long-term safety and sustained efficacy.
References
- ClinicalTrials.gov. REAL8 Study (NCT05330325)
- Medscape. FDA Okays Once-Weekly Tx for Turner Syndrome Growth Failure.
- PRNewswire. Novo’s Sogroya Receives FDA Approval for Turner Syndrome.
- EMPR. Once-Weekly Sogroya Approved for Growth Failure in Turner Syndrome.
- Contemporary Pediatrics. FDA Approves Once-Weekly Somapacitan for Children With Turner Syndrome.